PMID- 28950269
OWN - NLM
STAT- MEDLINE
DCOM- 20181009
LR  - 20181009
IS  - 2296-5262 (Electronic)
IS  - 2296-5270 (Linking)
VI  - 40
IP  - 10
DP  - 2017
TI  - The Revised International Staging System Compared to the Classical International 
      Staging System Better Discriminates Risk Groups among Transplant-Ineligible 
      Multiple Myeloma Patients.
PG  - 616-620
LID - 10.1159/000478935 [doi]
AB  - BACKGROUND: The Revised International Staging System (R-ISS) has recently been 
      introduced as a comprehensive prognostic score for multiple myeloma (MM). 
      Validation of the R-ISS in patients treated outside of clinical trials is the 
      focus of current investigations. The aim of this study was to test the prognostic 
      role of the R-ISS in MM patients ineligible for autologous stem cell 
      transplantation. PATIENTS AND METHODS: A total of 102 newly diagnosed MM patients 
      were analyzed. All patients were initially treated with thalidomide-based 
      combinations. RESULTS: An overall response rate was achieved in 77.4% patients. 
      Both the International Staging System (ISS) and the R-ISS influenced the 
      event-free survival and the overall survival (OS). However, the ISS was unable to 
      discriminate patients in stages ISS1 and ISS2 regarding OS. On the contrary, the 
      R-ISS clearly differentiated risk categories regarding OS and provided an 
      improved discriminative power of 6.3% compared to the ISS. Furthermore, among the 
      parameters that were significant in univariate analysis (presence of renal 
      impairment, anemia, platelet count < 130 x 109/l, and R-ISS), the multivariate 
      model pointed to the R-ISS (p = 0.001) as the most important parameter 
      influencing OS. CONCLUSION: The R-ISS represents a useful tool for risk 
      stratification of transplant-ineligible MM patients and should be considered as a 
      prognostic index in daily clinical practice.
CI  - (c) 2017 S. Karger GmbH, Freiburg.
FAU - Bila, Jelena
AU  - Bila J
AD  - Clinic of Hematology, ClinicalCenter Serbia, Belgrade, Serbia.
FAU - Jelicic, Jelena
AU  - Jelicic J
FAU - Dencic Fekete, Marija
AU  - Dencic Fekete M
FAU - Trajkovic, Goran
AU  - Trajkovic G
FAU - Sretenovic, Aleksandra
AU  - Sretenovic A
FAU - Perunicic Jovanovic, Maja
AU  - Perunicic Jovanovic M
FAU - Antic, Darko
AU  - Antic D
FAU - Mihaljevic, Biljana
AU  - Mihaljevic B
LA  - eng
PT  - Journal Article
DEP - 20170919
PL  - Switzerland
TA  - Oncol Res Treat
JT  - Oncology research and treatment
JID - 101627692
RN  - 4Z8R6ORS6L (Thalidomide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Eligibility Determination
MH  - Female
MH  - Germany
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/drug therapy/mortality/*pathology
MH  - Neoplasm Staging/*methods
MH  - Prognosis
MH  - *Risk Assessment
MH  - Thalidomide/administration & dosage
MH  - Transplant Recipients/*classification
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Multiple myeloma
OT  - Revised International Staging System
EDAT- 2017/09/28 06:00
MHDA- 2018/10/10 06:00
CRDT- 2017/09/27 06:00
PHST- 2017/05/02 00:00 [received]
PHST- 2017/06/23 00:00 [accepted]
PHST- 2017/09/28 06:00 [pubmed]
PHST- 2018/10/10 06:00 [medline]
PHST- 2017/09/27 06:00 [entrez]
AID - 000478935 [pii]
AID - 10.1159/000478935 [doi]
PST - ppublish
SO  - Oncol Res Treat. 2017;40(10):616-620. doi: 10.1159/000478935. Epub 2017 Sep 19.